Sun Pharma’s Lerodalcibep licensing
Sun Pharma secured rights to commercialise and manufacture Lerodalcibep worldwide, excluding the US and China; the once-monthly PCSK9 inhibitor treats adults. Analysts cited the licensing deal, US portfolio growth and tariff relief as potential stock drivers.
)
Timeline
Tuesday, 29 September
- Expanding innovative portfolio may drive gains for Sun Pharma stock
Lerodalcibep licensing, US portfolio growth and tariff relief are cited as potential stock drivers
)
Monday, 28 September
- Sun Pharma secures rights to commercialise Lerodalcibep outside the US and China
Sun Pharma will commercialise and manufacture Lerodalcibep worldwide, excluding the United States and China
